Recently, low IgE level has been a remarkable subject and a number of investigations have been carried on it. In our study, we aimed to identify the disease groups that might be associated with low IgE levels in children and adults. For this purpose, the patients whose IgE levels were determined in the last 5 years were screened. Among these, the patients with low IgE levels were analyzed for their diagnoses. Malignant and autoimmune disorders were detected in high rates. Low IgE levels did not show any correlation with the levels of other immunoglobulins. Autoimmune disorders were more frequent in patients who had autoantibodies, in females, and the ones with high IgG levels. The results of this study suggest that the role of IgE in the immune system, as well as its functions in malignancy and autoimmunity should be further clarified, and IgE deficiency should be taken seriously when encountered.
An IgE level <2.5 IU/mL is defined as IgE deficiency. Its prevalence has been determined as 2.4% in the US population over the age of 6 years [18]. This prevalence was reported as 1.95% in a meta-analysis analyzing a number of cohorts [5]. The patients included in our study were those whose IgE levels were measured for any reason in our hospital. Therefore, our results do not present the prevalence in our society. In our study, an IgE level <2.5 IU/mL was determined in 0.52% of the patients who had IgE level measurements.
The annual cancer diagnosis rate in Turkey is 0.28% [19]. The relationship between IgE level and cancer has been investigated in various studies. An inversely proportional relationship was shown between allergic sensitization and cancer development, high IgE levels were associated with a lower risk of multiple myeloma and Chronic Lymphoid Leukemia (CLL), and patients diagnosed with glioma and multiple myeloma had a longer life expectancy if their total IgE levels were high [20–25]. Studies that indicated high IgE and atopy might be protective against malignancy rationalised the opposite of this hypothesis, that is, the individuals with very low or undetectable IgE levels might have a higher malignancy prevalence and risk of developing tumors. When the patients with low IgE levels were compared with the ones with normal, high and very high IgE levels, a higher malignancy rate was found in the group with low IgE levels. It was reported that the group with IgE deficiency developed lymphoma (16%) most frequently, and myeloma (8%) was the second most common malignancy [26]. In a recent study, it was found that patients with IgE deficiency (<2.5 IU/ml = KU/L) developed malignant disorders more frequently compared to the ones with high (100 KU/L) and very high (1000 KU/L) IgE levels [9]. It was reported that the pre-diagnosis IgE levels were lower in cases diagnosed with CLL and multiple myeloma compared to the control group, and this was related to the clinical immunodeficiency observed before the diagnosis of cancer [27]. The relationship between IgE levels and cancer may indicate the role of T-Helper-2 mediated immune response in the development or control of some cancers. The studies conducted in line with this hypothesis have found that mice injected with breast cancer cells fight the tumor better and have a longer life span if they had a higher IgE level spontaneously [6]. Again, it was determined that tumor spread increased in mice whose IgE responses were destroyed, and tumor growth was well-controlled in mice with strong IgE responses [28]. There are more folate receptor alpha in many cancer cell types compared to the normal cells, and IgE type chimeric antibody (MOv18 IgE) phase 1 (ClinicalTrials.gov NCT02546921) trials have been carried out for this receptor [29]. Recently, numerous chimeric IgE studies have been carried out for use in cancer treatment [30].
In the light of all these data, the relationship between malignancy and IgE seems to be inversely proportional. The association of cancer (predominantly hematological cancers) with very low IgE levels appears to occur in absence of a known immunodeficiency. It is generally thought that atopy has a protective effect against cancer. In cases with very low IgE levels, there is a need for long-term prospective studies making repeated measurements and clinical follow-up of the patients order to determine whether malignancy is the result or cause, as well as studies that will reveal the unenlightened role of IgE in the immune system. We do not know whether IgE deficiency is a predisposing factor for cancer, or a sign of cancer prior to its development due to a modulation disorder in the immune system. In any case, in cases with IgE deficiency, this situation should be considered as a red flag, and the cases should be followed up closely in terms of cancer development even if the clinical picture is normal at that time.
The most common disorder in our patients was malignancies. Hematological malignancies were found in most of our patients, and solid tumors were less frequent. Among hematological malignancies; lymphoma, CLL and multiple myeloma were predominant. There were many solid tumor types.
In our study, autoimmune disorders were determined in 16.7% of the cases. As expected, this was found to be associated with autoantibody positivity, female gender and IgG elevation. Mainly, connective tissue disorders were evident. In the study of Smith et al. [3] the incidence of autoimmune disorders was found to be significantly higher in patients with low IgE levels compared to the control group. It is generally thought that there is an inversely proportional relationship between allergy and autoimmunity. It has been suggested that this relationship is T helper-induced, the Th2-mediated atopic disorders are less common in patients with Th1-mediated autoimmunity, and may prevent the development of autoimmunity or alleviate the clinical symptoms in allergic disorders where Th2 inflammation is more prominent [31,32]. In addition, it was claimed that gain-of-function mutation in the STAT3 is an immune deficiency accompanied by autoimmunity and recurrent infections. IgE level was found to be <2 IU/mL in the ones with this mutation, and it was reported that it could be used as a screening test [33]. In another study, it was suggested that it could not be used as a screening test since its sensitivity and specificity were low [34]. In literature, the studies on IgE and autoimmunity are mostly on the development of IgE type of autoantibodies in autoimmune disorders [12,35,36]. It has been reported that the presence of IgE type autoantibodies is associated with disease activity in autoimmune disorders, particularly in SLE [11]. We do not know how and why IgE deficiency occurs in autoimmunity when the levels of other immunoglobulins are high. However, as is known, the incidence of autoimmune disorders increases in humoral immune deficiencies (selective IgA deficiency, etc.). IgE, like IgA, is an immunoglobulin with a more pronounced mucosal activity. Lack of neutralization of extrinsic antigens in the mucosa may lead to the establishment of autoimmune mechanisms. Although IgE deficiency is not yet included in the classification of primary immunodeficiencies, signs of an immune dysregulation are seen in our study and in the literature.
The cases in the immunodeficiency group mostly had humoral immunodeficiencies. It is an expected finding that all immunoglobulins will be affected in humoral ID. IgE deficiency is frequently seen in CVID, and correlates with low levels of other immunoglobulins [5]. Other causes of humoral immunodeficiency, ataxia telangiectasia and combined immunodeficiencies may also lead to IgE deficiency [4].
Since IgE is a mucosal immunoglobulin, it may play a role in the immune response in case of exposure to exogenous antigens. It has been shown that IgE production is insufficient in mice with experimental lymphotoxin deficiency, these mice have more airway inflammation and bronchial hyperactivity, but the inflammation is Th1 type [37]. In our study, atopic diseases were determined in 20 (11.1%) patients, and airway disease was more common.
It has been determined that upper respiratory tract infections are more common in patients with very low IgE levels compared to patients with normal and high IgE levels [3,38]. In our study, mainly sino-pulmonary infections were determined. No parasitic infections were found. In the literature, it has been reported that sino-pulmonary infections are frequently encountered in cases with very low IgE levels [39,40]. The role of IgE in mucosal defense may explain this condition.
In our study, the other diseases group constituted 37.5% of the child patients. The most common disorders in this group were neurological diseases, and resistant epilepsies were the most frequently encountered disorders. In these cases, IgE deficiency may often be associated with the use of antiepileptics. Anti-epileptics have been shown to reduce immunoglobulin levels [41,42]. Another reason was congenital heart anomalies requiring surgery. Most of our patients had aortic arch anomalies. The genetic disease most commonly associated with aortic arch anomalies is DiGeorge syndrome, which also causes low immunoglobulin levels [43]. In these patients, low IgE levels may be secondary to unspecified complete or incomplete Di-George syndrome or intervention to thymus during surgery. Severe protein energy malnutrition was detected in three patients. In adults, chronic renal failure, complicated diabetes, and aplastic anemia were the most common disorders. It has been known that medications used for chronic renal failure, malnutrition, and following renal transplantation cause hypogammaglobinemia [42].
The main limitations of the study are its retrospective design and the absence of a control group; and this led to failure in standardization. The IgE measurements of the cases were made predominantly before the diagnosis and during the diagnostic procedures. However, test results obtained after diagnosis were also available. IgG, IgA, IgM levels, and autoantibodies were not measured in every patient, and this caused data loss. Both IgE and other tests were ordered as the clinicians decided, not according to a standard algorithm.
Another limitation the study was lack of the control group, and hence not designing the study as a randomized controlled study, and lack of comparison with the groups with normal and high IgE levels. However, while planning the study, we wanted to learn how very low IgE levels are reflected in the clinical picture. Therefore, we wanted to analyze only cases with IgE deficiency.
The fact that the data were obtained from a limited sample group and the lack of any information on the prevalence of IgE deficiency in our country were other limitations of our study.
We hope that our study will guide further studies on the role of IgE in the pathogenesis of diseases and also the studies on targeted therapies.